Filings & corporate actions
81 results filed
CSVNext results · Q2 FY27
Expected 21 Oct 2026 – 7 Nov 2026
Estimate: filed 21–38 days after quarter end, last 5 times
Dividend
₹9.00 per share · last 29 May 2026
2026
- 30 JulresultsResults · Q1 FY27 · consolidated and standalone+5.1%NSE
- 20 JulshareholdingShareholding · 20 Jul 2026+5.1%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026+5.1%NSE
- 29 MaydividendDividend · ₹9.00 per share-2.8%
- 23 MayresultsResults · Q4 FY26 · standalone+1.9%NSE
- 22 MayresultsResults · Q4 FY26 · consolidated+1.9%NSE
- 17 AprshareholdingShareholding · 31 Mar 2026+0.6%NSE
- 18 FebdividendDividend · ₹29.00 per share-1.1%
- 13 FebresultsResults · Q3 FY26 · consolidated and standalone+4.5%NSE
- 3 JanshareholdingShareholding · 31 Dec 2025-0.4%NSE
Reaction to results · all yearsrose on day 0 in 41 of 78 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 30 Jul 2026 | +5.1% | +1.1% | +3.7% | 1.7× |
| Q4 FY26 | 22 May 2026 | +1.9% | -3.8% | +0.6% | 3.6× |
| Q3 FY26 | 13 Feb 2026 | +4.5% | +5.6% | +5.6% | 5.4× |
| Q2 FY26 | 7 Nov 2025 | +6.6% | +6.7% | +5.0% | 10.3× |
| Q1 FY26 | 28 Jul 2025 | +4.0% | -0.9% | -1.3% | 3.1× |
| Q4 FY25 | 20 May 2025 | +1.5% | -2.3% | -0.4% | 3.4× |
| Q3 FY25 | 24 Jan 2025 | +2.8% | -1.3% | -6.4% | 6.0× |
| Q2 FY25 | 25 Oct 2024 | -3.4% | -6.8% | -6.1% | 2.6× |
| Q1 FY25 | 23 Jul 2024 | +0.2% | +1.1% | +7.1% | 4.1× |
| Q4 FY24 | 24 May 2024 | +1.6% | +2.5% | +8.3% | 5.6× |
| Q3 FY24 | 2 Feb 2024 | +4.7% | +3.7% | +6.6% | 2.4× |
| Q2 FY24 | 25 Oct 2023 | +2.4% | +2.3% | +12.5% | 5.2× |
| Q1 FY24 | 7 Aug 2023 | -0.5% | -3.2% | -6.3% | 2.2× |
| Q4 FY23 | 30 May 2023 | +7.1% | +5.2% | +14.0% | 16.0× |
| Q3 FY23 | 25 Jan 2023 | -1.2% | -1.6% | -4.9% | 1.5× |
| Q2 FY23 | 21 Oct 2022 | -0.4% | +7.2% | +3.0% | 0.1× |
| Q1 FY23 | 29 Jul 2022 | -0.2% | +1.7% | +0.4% | 1.4× |
| Q4 FY22 | 25 May 2022 | +10.1% | +6.9% | +8.4% | 15.8× |
| Q3 FY22 | 25 Jan 2022 | -15.1% | -14.4% | -15.6% | 20.8× |
| Q2 FY22 | 27 Oct 2021 | -4.2% | -4.8% | +3.1% | 3.3× |
| Q1 FY22 | 27 Jul 2021 | +2.7% | +2.4% | +1.7% | 4.6× |
| Q4 FY21 | 18 May 2021 | +1.1% | -0.5% | +6.1% | 7.4× |
| Q3 FY21 | 8 Feb 2021 | -6.4% | -6.1% | -11.5% | 6.0× |
| Q2 FY21 | 26 Oct 2020 | -2.1% | -3.0% | -2.7% | 2.2× |
| Q1 FY21 | 30 Jul 2020 | +9.3% | +20.7% | +11.2% | 14.7× |
| Q4 FY20 | 27 May 2020 | -6.9% | -10.6% | -4.6% | 3.4× |
| Q3 FY20 | 27 Jan 2020 | -5.5% | -4.9% | +11.0% | 6.1× |
| Q2 FY20 | 23 Oct 2019 | +5.2% | +7.2% | +4.8% | 3.0× |
| Q1 FY20 | 23 Jul 2019 | +9.5% | +13.8% | +13.1% | 8.9× |
| Q4 FY19 | 20 May 2019 | -3.2% | -7.9% | -9.4% | 6.2× |
| Q3 FY19 | 31 Jan 2019 | -1.1% | -1.2% | -1.8% | 0.9× |
| Q2 FY19 | 19 Nov 2018 | +0.7% | -0.5% | +4.1% | 0.3× |
| Q1 FY19 | 8 Aug 2018 | -1.1% | +2.7% | +4.0% | 1.9× |
| Q4 FY18 | 2 Jul 2018 | +1.2% | +3.2% | +6.1% | 0.4× |
| Q3 FY18 | 15 Feb 2018 | +0.2% | -5.9% | -11.2% | 2.4× |
| Q2 FY18 | 6 Nov 2017 | -2.7% | -4.1% | -1.5% | 1.4× |
| Q1 FY18 | 18 Aug 2017 | -3.1% | -5.6% | -5.1% | 0.8× |
| Q4 FY17 | 18 Jun 2017 | -0.9% | -2.2% | +6.9% | 0.5× |
| Q3 FY17 | 7 Feb 2017 | +0.2% | -1.9% | +5.2% | 2.7× |
| Q2 FY17 | 22 Dec 2016 | -2.2% | -3.3% | -1.5% | 1.2× |
| Q1 FY17 | 21 Sept 2016 | +2.0% | +0.4% | -0.3% | 1.4× |
| Q4 FY16 | 26 May 2016 | -0.3% | 0.0% | -4.4% | 1.3× |
| Q3 FY16 | 8 Feb 2016 | -2.4% | -5.3% | -4.5% | 0.9× |
| Q2 FY16 | 30 Oct 2015 | -0.3% | +0.6% | -3.7% | 1.5× |
| Q1 FY16 | 29 Jul 2015 | +1.0% | +4.5% | +12.9% | 1.1× |
| Q4 FY15 | 20 May 2015 | 0.0% | -0.5% | +7.4% | 0.4× |
| Q3 FY15 | 5 Feb 2015 | -2.6% | +3.8% | -1.4% | 0.6× |
| Q2 FY15 | 10 Nov 2014 | +2.1% | +7.7% | +12.0% | 0.5× |
| Q1 FY15 | 7 Aug 2014 | -0.4% | +0.6% | +15.5% | 0.8× |
| Q4 FY14 | 12 May 2014 | +2.6% | -5.7% | +3.9% | 4.0× |
| Q3 FY14 | 22 Jan 2014 | +6.7% | +0.4% | +7.8% | 6.6× |
| Q2 FY14 | 6 Nov 2013 | -0.8% | -5.6% | +1.5% | 0.4× |
| Q1 FY14 | 1 Aug 2013 | +2.1% | -2.0% | -4.9% | 0.8× |
| Q4 FY13 | 19 Jun 2013 | -0.7% | -3.5% | +6.3% | 1.5× |
| Q3 FY13 | 30 Jan 2013 | -2.2% | -6.5% | -5.4% | 2.7× |
| Q2 FY13 | 29 Oct 2012 | +0.4% | +1.6% | -2.2% | 0.6× |
| Q1 FY13 | 24 Jul 2012 | +4.7% | +5.5% | +7.7% | 1.4× |
| Q4 FY12 | 21 May 2012 | -2.4% | +0.2% | -4.4% | 3.0× |
| Q3 FY12 | 23 Jan 2012 | -0.5% | +3.0% | +1.7% | 0.3× |
| Q2 FY12 | 19 Oct 2011 | +1.0% | +1.0% | -0.4% | 4.4× |
| Q1 FY12 | 1 Aug 2011 | -1.5% | -4.9% | -8.3% | 1.0× |
| Q4 FY11 | 30 May 2011 | +5.8% | +1.1% | +7.2% | 11.7× |
| Q3 FY11 | 19 Jan 2011 | -5.6% | -5.7% | -11.1% | 1.6× |
| Q2 FY11 | 25 Oct 2010 | -1.4% | -2.0% | -1.1% | 0.2× |
| Q1 FY11 | 30 Jul 2010 | -1.8% | -1.4% | -3.7% | 2.8× |
| Q4 FY10 | 6 May 2010 | +0.4% | +3.1% | +7.9% | 1.1× |
| Q3 FY10 | 27 Jan 2010 | +4.8% | +6.8% | 0.0% | 2.8× |
| Q2 FY10 | 31 Oct 2009 | +2.5% | +13.9% | +19.0% | 1.3× |
| Q1 FY10 | 29 Jul 2009 | +7.8% | +2.1% | +28.9% | 4.3× |
| Q4 FY09 | 15 May 2009 | +3.1% | +17.6% | +19.3% | 1.4× |
| Q3 FY09 | 28 Jan 2009 | -0.3% | -4.2% | -0.5% | 0.8× |
| Q2 FY09 | 24 Oct 2008 | -7.5% | +5.6% | -8.1% | 0.5× |
| Q1 FY09 | 29 Jul 2008 | +2.8% | +6.2% | +18.1% | 2.6× |
| Q4 FY08 | 6 May 2008 | -3.2% | -6.2% | -14.3% | 8.7× |
| Q3 FY08 | 31 Jan 2008 | -0.9% | -4.5% | -1.3% | 0.9× |
| Q2 FY08 | 30 Oct 2007 | +3.4% | +3.0% | -0.9% | 1.9× |
| Q1 FY08 | 31 Jul 2007 | +0.5% | -3.0% | -8.2% | 1.4× |
| Q4 FY07 | 23 May 2007 | +4.5% | +29.6% | +19.8% | 5.6× |
| Average | +0.6% | +0.7% | +2.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+54.8%
Profit YoY+3.3%
Interest cost YoY+172.1%
Revenue QoQ+17.3%
Profit QoQ+55.5%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +19.6% | +16.8% | — | +14.2% | +12.0% | +10.5% |
| Profit | +11.5% | +19.6% | — | +11.3% | +11.4% | +23.6% |
Key data
CSVOpen4,763.50
Day range4,702.50 – 4,788.30
52-week range3,480.60 – 5,250.00
From 52w high-9.1%
RSI (14)41.5
ATR (14)106.74
Volume3.03L
Avg volume (20D)3.56L
Rel volume0.85×
Volatility (1Y)22.1%
Turnover₹144.4Cr
SMA 50 / 2004,926.18 / 4,445.98
Delivery percentage
Latest · 6 Oct 202655.1%
20-day avg61.0%
1-year avg57.2%
Percentile (own history)63rd
Range8.4–86.6%
Sessions1,731
Over the last 20 sessions TORNTPHARM settled 61.0% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 57.2%, so recent sessions are running 3.8 points higher than usual. The latest session ranks higher than 63% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | 0.00% | -1.99% | -2.72% | -1.74% | +19.68% | +34.01% |
Valuation
CSVMarket cap₹1.82L Cr
P/E (TTM)84.2
EPS (TTM)56.68
Shares outstanding33.85Cr
Listed25 Nov 2002
Ownership
CSVPromoter60.78%
Promoter Δ QoQ-7.53 pp
Public39.22%
FII17.97%
DII12.87%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 3,302.0 | 3,303.0 | 4,197.0 | 4,921.0 |
| YoY chg | +14.3% | +17.6% | +41.8% | +54.8% |
| Net profit (₹ Cr) | 591.0 | 635.0 | 364.0 | 566.0 |
| YoY chg | +30.5% | +26.2% | -26.9% | +3.3% |
| Net margin | 17.9% | 19.2% | 8.7% | 11.5% |
| EPS | 17.45 | 18.77 | 11.51 | 14.87 |
Shareholding over time
CSVBy quarter
20 Jul 2026 · promoter 60.78% · public 39.22%2021-092026-07
- Promoter
- Public and others
- Promoter
- 60.78%
- Public
- 39.22%
- Promoter change
- -7.53 pp
- Filed
- 20 Jul 2026
- FII
- 17.97%
- DII
- 12.87%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 2,660.0 | 2,732.0 | 2,745.0 | 2,859.0 | 2,889.0 | 2,809.0 | 2,959.0 | 3,178.0 | 3,302.0 | 3,303.0 | 4,197.0 | 4,921.0 | |
| Other income | 26.0 | (33.0) | 31.0 | 24.0 | (16.0) | 33.0 | (18.0) | (37.0) | (27.0) | (13.0) | (17.0) | (12.0) | |
| Total income | 2,686.0 | 2,699.0 | 2,776.0 | 2,883.0 | 2,873.0 | 2,842.0 | 2,941.0 | 3,141.0 | 3,275.0 | 3,290.0 | 4,180.0 | 4,909.0 | |
| Total expenses | 2,127.0 | 2,156.0 | 2,145.0 | 2,227.0 | 2,212.0 | 2,151.0 | 2,252.0 | 2,403.0 | 2,471.0 | 2,466.0 | 3,585.0 | 4,155.0 | |
| └ Finance costs | 91.0 | 80.0 | 80.0 | 75.0 | 64.0 | 57.0 | 56.0 | 56.0 | 48.0 | 45.0 | 236.0 | 305.0 | |
| └ Depreciation | 201.0 | 213.0 | 203.0 | 197.0 | 198.0 | 199.0 | 201.0 | 201.0 | 204.0 | 206.0 | 508.0 | 593.0 | |
| Profit before tax | 559.0 | 631.0 | 631.0 | 656.0 | 661.0 | 691.0 | 665.0 | 738.0 | 791.0 | 814.0 | 529.0 | 733.0 | |
| Tax expense | 173.0 | 188.0 | 182.0 | 199.0 | 208.0 | 188.0 | 167.0 | 190.0 | 200.0 | 179.0 | 165.0 | 167.0 | |
| Net profit | 386.0 | 443.0 | 449.0 | 457.0 | 453.0 | 503.0 | 498.0 | 548.0 | 591.0 | 635.0 | 364.0 | 566.0 | |
| EPS | 11.39 | 13.10 | 13.27 | 13.51 | 13.37 | 14.88 | 14.71 | 16.19 | 17.45 | 18.77 | 11.51 | 14.87 | |
| Net margin | 14.51% | 16.22% | 16.36% | 15.98% | 15.68% | 17.91% | 16.83% | 17.24% | 17.90% | 19.22% | 8.67% | 11.50% | |
| PBT margin | 21.02% | 23.10% | 22.99% | 22.95% | 22.88% | 24.60% | 22.47% | 23.22% | 23.96% | 24.64% | 12.60% | 14.90% | |
| Tax rate | 30.95% | 29.79% | 28.84% | 30.34% | 31.47% | 27.21% | 25.11% | 25.75% | 25.28% | 21.99% | 31.19% | 22.78% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 30 Jul 2026.
TORNTPHARM at a glance
- TORNTPHARM closed at ₹4,772 on 6 Oct 2026, 0.00% on the day, +34.0% over one year, 9.1% below its 52-week high of ₹5,250.
- Delivery was 55.1% of traded quantity on 6 Oct 2026, the 63rd percentile of its own 1,731 sessions with a reading (20-session average 61.0%, 1-year average 57.2%).
- Market capitalisation is ₹1.82 lakh crore at a trailing P/E of 84.2 (trailing EPS ₹56.68).
- Q1 FY27 results (consolidated, filed 30 Jul 2026): revenue ₹4,921 crore (+54.8% year on year), net profit ₹566 crore (+3.3%); the price moved +5.1% on the first session after.
- Promoters held 60.78% at 20 Jul 2026, down 7.53 percentage points on the previous filing.
- Q2 FY27 results are expected between 21 Oct 2026 and 7 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE685A01028
SeriesEQ
Listed25 Nov 2002
History from3 Jan 1995
Sessions7,813
Turnover rank#167
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
- MANKINDMankind Pharma Limited2,500.00+0.85%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE